No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ACLX241220P75000
- 2.12
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
0.00Open2.12Pre Close0 Volume222 Open Interest75.00Strike Price0.00Turnover6341.23%IV6.98%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-10DDays to Expiry2.12Extrinsic Value100Contract SizeAmericanOptions Type-0.4526Delta0.0671Gamma36.96Leverage Ratio-2160.1023Theta0.0000Rho-16.73Eff Leverage0.0004Vega
Intraday
- 5D
- Daily
News
Buy Rating for Arcellx Inc. Based on Promising Efficacy and Safety of BCMA CAR-T Therapy in IMMagine-1 Study
Morgan Stanley Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $111
Truist Financial Initiates Arcellx(ACLX.US) With Buy Rating
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $111 to $122
Arcellx Inc (ACLX) Gets a Buy From Truist Financial
Promising Outlook for Arcellx Inc: Anito-cel Therapy Positioned as a Safer Alternative With Strong Market Potential